Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Реальное исследование фослеводопы/фоскарбидопы для оценки исходов качества жизни у взрослых участников на более ранних стадиях прогрессирующей болезни Паркинсона (PUCCINI)

6 ноября 2026 г. обновлено: AbbVie

Глобальное исследование реальной клинической практики по эффективности и безопасности/переносимости фослеводопы/фоскарбидопы у пациентов на ранних стадиях прогрессирования болезни Паркинсона

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.

There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being

Обзор исследования

Статус

Рекрутинг

Тип исследования

Наблюдательный

Регистрация (Оцененный)

100

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Lars Bergmann
  • Номер телефона: +49(0)170 4538568
  • Электронная почта: lars.bergmann@abbvie.com

Места учебы

      • Jerusalem, Израиль, 91120
        • Рекрутинг
        • Hadassah Medical Center-Hebrew University /ID# 276211
    • Jerusalem
      • Jerusalem, Jerusalem, Израиль, 91031
        • Рекрутинг
        • Shaare Zedek Medical Center /ID# 276209
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Израиль, 5265601
        • Рекрутинг
        • The Chaim Sheba Medical Center /ID# 276210
      • Tel Aviv, Tel Aviv, Израиль, 6423906
        • Рекрутинг
        • Tel Aviv Sourasky Medical Center /ID# 276212
    • Barcelona
      • Sant Joan Despí, Barcelona, Испания, 08970
        • Рекрутинг
        • Hospital de Sant Joan Despi Moises Broggi /ID# 276895
    • Ontario
      • Toronto, Ontario, Канада, M5T 2S8
        • Рекрутинг
        • Toronto Western Hospital /ID# 278384
    • Quebec
      • Sherbrooke, Quebec, Канада, J1H 5N4
        • Рекрутинг
        • CIUSSS de l Estrie - CHUS /ID# 278379
      • Guaynabo, Пуэрто-Рико, 00969
        • Рекрутинг
        • Centro Internacional De Mercadeo /ID# 276088
      • Brasov, Румыния, 500326
        • Рекрутинг
        • Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499
    • Bucharest
      • Bucharest, Bucharest, Румыния, 022328
        • Рекрутинг
        • Fundeni Clinical Institute /ID# 277490
    • Iaşi
      • Iași, Iaşi, Румыния, 700620
        • Рекрутинг
        • Arcadia Spitale Si Centre Medicale /Id# 277525
    • Timiș County
      • Timișoara, Timiș County, Румыния, 300724
        • Рекрутинг
        • Neurotim Med /ID# 277500
      • Newcastle upon Tyne, Соединенное Королевство, NE3 3HD
        • Рекрутинг
        • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752
    • Devon
      • Plymouth, Devon, Соединенное Королевство, PL6 8DH
        • Рекрутинг
        • University Hospitals Plymouth NHS Trust /ID# 284977
    • Hammersmith and Fulham
      • London, Hammersmith and Fulham, Соединенное Королевство, W6 8RF
        • Рекрутинг
        • Charing Cross Hospital /ID# 284211
    • Florida
      • Boca Raton, Florida, Соединенные Штаты, 33486
        • Рекрутинг
        • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190
      • Tampa, Florida, Соединенные Штаты, 33613
        • Рекрутинг
        • University of South Florida- Neuroscience Institute /ID# 278562
    • North Carolina
      • Charlotte, North Carolina, Соединенные Штаты, 28207-1196
        • Рекрутинг
        • Novant Health /ID# 278567
    • Texas
      • Georgetown, Texas, Соединенные Штаты, 78628
        • Рекрутинг
        • Texas Movement Disorder Specialists /ID# 278565
    • City of Zagreb
      • Grad Zagreb, City of Zagreb, Хорватия, 10000
        • Рекрутинг
        • Klinicka Bolnica Dubrava /ID# 278408
    • Primorje-Gorski Kotar County
      • Rijeka, Primorje-Gorski Kotar County, Хорватия, 51000
        • Рекрутинг
        • Klinicki Bolnicki Centar Rijeka /ID# 278277
      • Kanagawa, Япония, 231-0063
        • Рекрутинг
        • Noge General Medicine and Neurology /ID# 280741
      • Tokushima, Япония, 770-0852
        • Рекрутинг
        • Itsuki Hospital /ID# 280743
      • Tokyo, Япония, 202-0004
        • Рекрутинг
        • Miwa Internal Medicine Clinic /ID# 280740
    • Saitama
      • Iruma-gun, Saitama, Япония, 3500495
        • Рекрутинг
        • Saitama Medical University Hospital /ID# 280624
    • Tokyo
      • Bunkyo-ku, Tokyo, Япония, 113-8431
        • Рекрутинг
        • Juntendo University Hospital /ID# 280623

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 69 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Метод выборки

Невероятностная выборка

Исследуемая популяция

Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.

Описание

Inclusion Criteria:

  • Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
  • A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
  • Adult male or female between 18 and 69 years of age
  • Disease duration (time since diagnosis) <10 years
  • Time since motor fluctuations started ≤5 years
  • H&Y Stage <3 in best "on"
  • "off" time of ≤ 4.5 hours per day
  • Naïve to LDp/CDp
  • Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
  • Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
  • Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
  • Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered

Exclusion Criteria:

  • History of any condition included in the contraindications section of the approved local Foslevodopa/Foscarbidopa (LDp/CDp) label in the participating country
  • History of treatment with any Device-Aided Therapy (DAT), such as Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa/Carbidopa Intestinal Gel (LCIG)/ Carbidopa/Levodopa Enteral Suspension (CLES), Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG)
  • Mini-Mental State Examination (MMSE) score <24
  • Participation in a concurrent investigational or observational clinical trial
  • Lack of motivation/insufficient language skills to complete the study questionnaires
  • History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis). In case of temporary affections like recent sunburn or open wounds, or in case of permanent affections like acne, scar tissue, tattoo, branding, or colorations, the participant should not be included if the Investigator considers these as interfering with infusion of study drug or study assessments.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Наблюдательные модели: COHORT
  • Временные перспективы: PROSPECTIVE

Когорты и вмешательства

Группа / когорта
Foslevodopa/Foscarbidopa

Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore
Временное ограничение: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores
Временное ограничение: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score
Временное ограничение: Up to approximately 6 months

The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score
Временное ограничение: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Временное ограничение: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)
Временное ограничение: Up to approximately 6 months

The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening.

Up to approximately 6 months
Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Временное ограничение: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
Временное ограничение: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.
Временное ограничение: Up to approximately 6 months

The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.
Временное ограничение: Up to approximately 6 months

Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe.

Up to approximately 6 months
Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire
Временное ограничение: Up to approximately 6 months

The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.
Временное ограничение: Up to approximately 6 months

The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse.

Up to approximately 6 months

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.
Временное ограничение: Up to approximately 6 months

Measured by dedicated questionnaire.

Up to approximately 6 months
Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12
Временное ограничение: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale
Временное ограничение: Up to approximately 6 months

The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy).

Up to approximately 6 months
Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)
Временное ограничение: Up to approximately 6 months

Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident.

Up to approximately 6 months
Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale
Временное ограничение: Up to approximately 6 months

The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living.

Up to approximately 6 months
Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)
Временное ограничение: Up to approximately 6 months

Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options.

Up to approximately 6 months
Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Временное ограничение: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Healthcare Resource Utilization (HRU)
Временное ограничение: Up to approximately 6 months

Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists.

Up to approximately 6 months
Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)
Временное ограничение: Up to approximately 6 months

Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6

Up to approximately 6 months
Questionnaire to investigate the practicalities of the infusion system
Временное ограничение: Up to approximately 6 months

Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments).

Up to approximately 6 months
Number of Participants with Adverse Events (AEs)
Временное ограничение: Up to approximately 6 months

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately 6 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: ABBVIE INC., AbbVie

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

3 августа 2026 г.

Первичное завершение (Оцененный)

1 октября 2027 г.

Завершение исследования (Оцененный)

1 октября 2027 г.

Даты регистрации исследования

Первый отправленный

10 ноября 2025 г.

Впервые представлено, что соответствует критериям контроля качества

12 ноября 2025 г.

Первый опубликованный (Действительный)

13 ноября 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

10 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

6 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕ РЕШЕНО

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

продукт, произведенный в США и экспортированный из США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться